News & Updates

Treatment with the GLP-1 receptor agonist semaglutide appears safe for patients initiating dialysis, as demonstrated in a pooled analysis presented at EASD 2025.

New research suggests that engaging in moderate-to-vigorous physical activity can counteract the harmful association between sedentary behaviour and dyslipidaemia by promoting a healthier, more diverse community of gut bacteria.

The melanocortin-4 receptor agonist setmelanotide has demonstrated long-term clinical benefit and an acceptable safety profile in adults with monogenic or syndromic obesity, reports a study.

New drug applications approved by US FDA as of 16-30 September 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Women with a history of preterm delivery, hypertensive disorders of pregnancy, and several other pregnancy complications face an increased long-term risk of atrial fibrillation (AF), as suggested in a study.

Combination treatment with cagrilintide and semaglutide significantly reduced body weight in patients with overweight or obesity and type 2 diabetes (T2D), according to the REDEFINE 2 trial presented at EASD 2025.